Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, Allred S, Huang LY, Hahn J, Gahnberg K, Treuting PM, Trueblood ES, Gosink JJ, Thurman R, Wo S, Spahr K, Haass EJ, Snead K, Miller D, Padilla M, Smith AJ, Frantz C, Schrum JP, Nazarenko N, Gardai SJ. Gray E, et al. Among authors: ulrich m. J Immunother Cancer. 2023 Oct;11(10):e007572. doi: 10.1136/jitc-2023-007572. J Immunother Cancer. 2023. PMID: 37793853 Free PMC article.
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer.
Olson D, Taylor J, Willis K, Hensley K, Allred S, Zaval M, Farr L, Thurman R, Jain N, Hein R, Ulrich M, Peterson S, Kulukian A. Olson D, et al. Among authors: ulrich m. Cancer Res Commun. 2023 Sep 25;3(9):1927-1939. doi: 10.1158/2767-9764.CRC-23-0302. Cancer Res Commun. 2023. PMID: 37721518 Free PMC article.
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR. Li F, et al. Among authors: ulrich m. Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15. Mol Cancer Ther. 2018. PMID: 29142066
Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates.
Neumann CS, Olivas KC, Anderson ME, Cochran JH, Jin S, Li F, Loftus LV, Meyer DW, Neale J, Nix JC, Pittman PG, Simmons JK, Ulrich ML, Waight AB, Wong A, Zaval MC, Zeng W, Lyon RP, Senter PD. Neumann CS, et al. Mol Cancer Ther. 2018 Dec;17(12):2633-2642. doi: 10.1158/1535-7163.MCT-18-0643. Epub 2018 Sep 21. Mol Cancer Ther. 2018. PMID: 30242091
Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis.
Carroll PA, Diolaiti D, McFerrin L, Gu H, Djukovic D, Du J, Cheng PF, Anderson S, Ulrich M, Hurley JB, Raftery D, Ayer DE, Eisenman RN. Carroll PA, et al. Among authors: ulrich m. Cancer Cell. 2015 Feb 9;27(2):271-85. doi: 10.1016/j.ccell.2014.11.024. Epub 2015 Jan 29. Cancer Cell. 2015. PMID: 25640402 Free PMC article.
592 results